Heparan sulfate proteoglycans as trastuzumab targets in anoikis-resistant endothelial cells
Jessica Oyie Sousa Onyeisi1, Paulo Castanho de Almeida Pernambuco Filho2, Silvana de Araujo Lopes2
1Disciplina de Biologia Molecular, Departamento de Bioquímica, Universidade Federal de São Paulo, São Paulo, Brazil.
Abstract:
Anoikis is a form of programmed cell death induced by loss of contact from neighboring cells or from their extracellular matrix (ECM). Many tumorigenic cells are anoikis resistant, facilitating cancer progression and metastasis. Trastuzumab is a monoclonal antibody used for the treatment of breast and gastric cell cancer, but its mechanism of action is not well elucidated and its target molecules not well defined. Heparan sulfate proteoglycans (HSPGs) and glycosaminoglycans (GAGs) play important roles in tumor development and in response of cancer cells to drugs. This study investigates the effect of trastuzumab on the expression of HSPGs and sulfated glycosaminoglycans (SGAGs) in anoikis-resistant endothelial cells. After trastuzumab treatment, endothelial cells resistant to anoikis show an increase in adhesion to fibronectin followed by a decrease in invasion, proliferation, and angiogenic capacity. In addition, a significant increase in the number of cells in the S phase of the cell cycle was also observed. In relation to HSPGs and SGAGs expression, we observed a decrease in syndecan-4 and perlecan expression, as well as in the heparan sulfate biosynthesis in anoikis-resistant endothelial cells after exposure to trastuzumab. Our results suggest that trastuzumab interacts with GAGs and proteoglycans of the cell surface and ECM and through this interaction controls cellular events in anoikis-resistant endothelial cells.
Insights
Trastuzumab treatment reduces invasion and proliferation in anoikis-resistant endothelial cells by altering heparan sulfate proteoglycans (HSPGs) and glycosaminoglycans (GAGs). This impacts cancer progression and metastasis.
Area of Science:
- Cell Biology
- Cancer Research
- Biochemistry
Background:
- Anoikis resistance is crucial for cancer cell metastasis.
- Trastuzumab is a cancer therapeutic, but its precise molecular targets remain unclear.
- Heparan sulfate proteoglycans (HSPGs) and glycosaminoglycans (GAGs) influence tumor development and drug response.
Purpose of the Study:
- To investigate the effects of trastuzumab on HSPGs and sulfated glycosaminoglycans (SGAGs) in anoikis-resistant endothelial cells.
- To elucidate trastuzumab's mechanism of action in the context of anoikis resistance.
Main Methods:
- Treatment of anoikis-resistant endothelial cells with trastuzumab.
- Assessment of cell adhesion, invasion, proliferation, and angiogenic capacity.
- Cell cycle analysis.
- Quantification of HSPGs, SGAGs, and heparan sulfate biosynthesis.
Main Results:
- Trastuzumab increased fibronectin adhesion and decreased invasion, proliferation, and angiogenesis.
- A significant increase in S-phase cells was observed.
- Trastuzumab reduced syndecan-4 and perlecan expression and heparan sulfate biosynthesis.
Conclusions:
- Trastuzumab interacts with cell surface and ECM GAGs and proteoglycans.
- This interaction modulates cellular events in anoikis-resistant endothelial cells, potentially impacting cancer progression.
Related Concept Videos
Proteoglycans
Matrix Proteoglycans and Glycoproteins
Sulfate Attack on Concrete
Sulfates from sources like soil, groundwater, or industrial effluents...
Resistivity
Resistance
Target Cell Response to Hormones
Notably, the cellular response can be regulated by altering the number of receptors expressed in the cell. For example, prolonged exposure to elevated hormone levels results in a gradual decline or down-regulation in the number of receptors for that specific hormone on the cell surface. Conversely, in response to low hormone levels, cells may use up-regulation, producing an...


